CR Double-Crane(SH:600062) Sou Hu Cai Jing·2025-12-09 10:06Core Viewpoint - China Resources Double Crane (华润双鹤) has announced that its controlled company, Henan Zhongshuai Pharmaceutical Co., Ltd., has successfully included its drug, Methylphenidate Hydrochloride Extended-Release Capsules, in the National Medical Insurance Directory, which is expected to enhance product promotion and sales, although it is not anticipated to have a significant impact on the company's 2025 financial performance [1]. Group 1 - As of December 9, 2025, China Resources Double Crane's stock closed at 18.63 yuan, down 0.59% from the previous trading day, with a total market capitalization of 19.352 billion yuan [1]. - The stock opened at 18.74 yuan, reached a high of 18.79 yuan, and a low of 18.61 yuan, with a trading volume of 82.2435 million yuan and a turnover rate of 0.43% [1]. - The newly included drug is indicated for Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and above, with the agreement effective from January 1, 2026, to December 31, 2027 [1]. Group 2 - The drug was approved for market launch on January 8, 2025, and generated sales revenue of 12.4 million yuan in the first three quarters of 2025, accounting for approximately 0.15% of the company's total revenue during the same period [1]. - Inclusion in the medical insurance directory is expected to facilitate product promotion and sales, although it is projected to have no major impact on the company's operating performance for 2025 [1].